Roche News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

23.03.20	Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia (GlobeNewswire)
19.03.20	Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia (GlobeNewswire)
17.03.20	Roche Generalversammlung 2020 (GlobeNewswire)
17.03.20	Roche Annual General Meeting 2020 (GlobeNewswire)
16.03.20	Roche Generalversammlung 2020: Abstimmung durch die unabhängige Stimmrechtsvertreterin. Teilnahme vor Ort ist nach Verordnung des Bundesrates weder möglich noch erlaubt (GlobeNewswire)
16.03.20	Roche Annual General Meeting 2020: Voting will take place by independent proxy. Participation on site is neither possible nor permitted by Federal Council ordinance (GlobeNewswire)
14.03.20	Generalversammlung 2020 findet unter behördlichen Auflagen statt – elektronische Stimmabgabe dringend empfohlen (GlobeNewswire)
14.03.20	Roche Annual General Meeting 2020 to take place under special conditions set by the authorities - electronic voting strongly recommended (GlobeNewswire)
13.03.20	Roche’s cobas SARS-CoV-2 Test to detect novel coronavirus receives FDA Emergency Use Authorization and is available in markets accepting the CE mark (GlobeNewswire)
12.03.20	European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia (GlobeNewswire)
11.03.20	Roche receives FDA approval for CINtec PLUS Cytology test to aid clinicians in improving cervical cancer prevention (GlobeNewswire)
04.03.20	FDA grants Breakthrough Device Designation for Roche's Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma (GlobeNewswire)
25.02.20	FDA accepts Roche’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer (GlobeNewswire)
19.02.20	FDA grants priority review to Roche’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer (GlobeNewswire)
14.02.20	China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer (GlobeNewswire)
10.02.20	Roche provides topline results from investigator-led Phase II/III trial with gantenerumab in rare inherited form of Alzheimer’s disease (GlobeNewswire)
06.02.20	Roche’s risdiplam showed significant improvement in motor function in people aged 2-25 with type 2 or 3 spinal muscular atrophy (GlobeNewswire)
30.01.20	Roche mit sehr gutem Jahresergebnis für 2019 (GlobeNewswire)
30.01.20	Roche reports very strong results in 2019 (GlobeNewswire)
27.01.20	Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer (GlobeNewswire)
24.01.20	Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer (GlobeNewswire)
23.01.20	Roche’s Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy (GlobeNewswire)
21.01.20	European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma (GlobeNewswire)
13.01.20	Roche and Illumina partner to broaden patient access to genomic testing (GlobeNewswire)
23.12.19	Roche enters licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy (GlobeNewswire)
19.12.19	European Commission approves Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment (GlobeNewswire)
17.12.19	Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy (GlobeNewswire)
17.12.19	Roche purchases shares in tender offer for Spark Therapeutics, Inc. (GlobeNewswire)
16.12.19	Roche and Spark Therapeutics, Inc. announce closing of investigation and unconditional clearance by the FTC and expiration of Hart-Scott-Rodino waiting period for acquisition of Spark Therapeutics, In (GlobeNewswire)
16.12.19	Roche and Spark Therapeutics, Inc. announce unconditional clearance by UK Competition and Markets Authority (GlobeNewswire)
13.12.19	Roche announces positive Phase III study results for Tecentriq plus Cotellic and Zelboraf in people with previously untreated BRAF V600 mutation-positive advanced melanoma (GlobeNewswire)
12.12.19	Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer (GlobeNewswire)
11.12.19	APHINITY six-year results strengthen evidence of clinical benefit with Roche’s Perjeta-based regimen (GlobeNewswire)
10.12.19	Roche receives CE Mark for its Accu-Chek SugarView app (GlobeNewswire)
09.12.19	Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. to December 16, 2019 (GlobeNewswire)
09.12.19	Changes in the Board of Directors and the Corporate Executive Committee of Roche (GlobeNewswire)
09.12.19	Änderungen im Verwaltungsrat und in der Konzernleitung von Roche (GlobeNewswire)
08.12.19	New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia (GlobeNewswire)
04.12.19	FDA approves Roche’s Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer (GlobeNewswire)
02.12.19	Positive phase III results for Roche’s satralizumab in neuromyelitis optica spectrum disorder published in the New England Journal of Medicine (GlobeNewswire)
25.11.19	FDA grants priority review to Roche’s risdiplam for spinal muscular atrophy (GlobeNewswire)
22.11.19	Roche presents pivotal data demonstrating Tecentriq in combination with Avastin improves overall survival in people with the most common form of liver cancer (GlobeNewswire)
22.11.19	Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. (GlobeNewswire)
18.11.19	Roche to present new and updated data for seven approved and investigational medicines across multiple types of breast cancer at the 2019 San Antonio Breast Cancer Symposium (GlobeNewswire)
15.11.19	CHMP recommends EU approval of Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment (GlobeNewswire)
15.11.19	CHMP recommends conditional EU approval of Roche’s Polivy for people with previously treated aggressive lymphoma (GlobeNewswire)
11.11.19	Roche’s Gazyva (obinutuzumab), in combination with standard of care, more than doubles the percentage of lupus nephritis patients achieving complete renal response, compared to standard of care alone (GlobeNewswire)
11.11.19	Roche’s risdiplam meets primary endpoint in pivotal SUNFISH trial in people with type 2 or 3 spinal muscular atrophy (GlobeNewswire)
06.11.19	Roche to present new data highlighting breadth of haematology portfolio and pipeline at the American Society of Hematology 2019 Annual Meeting (GlobeNewswire)
30.10.19	Roche’s marketing applications for satralizumab in neuromyelitis optica spectrum disorder accepted for review by EMA and FDA (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20:03		Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones
18:01		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
17:58		Handel in Europa: STOXX 50 schliesst im Minus
17:58		Schwacher Handel: SMI schliesst mit Verlusten
17:58		Verluste in Europa: Euro STOXX 50 letztendlich leichter
17:58		SPI-Handel aktuell: SPI zum Handelsende leichter
17:58		Minuszeichen in London: FTSE 100 schwächelt zum Ende des Freitagshandels
15:58		SPI-Handel aktuell: SPI verliert